Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

STX-1150

Phase 1Small molecule

MMonash University

STX-1150 is one of 13 small molecule programs targeting Cholesterol. It is currently in Phase 1.

1

Indications

1

Total Trials

1

Active Trials

12

Competitors

Pipeline

Status by Indication[3][1]

Indication

CholesterolRecruiting

CholesterolPhase 1

Recruiting

Competition

Competitive Landscape

13 competitors in Cholesterol

#DrugCompanyPhaseTrials

Repatha

Zetia

OOrganon and Co

Crestor

Plavix

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Atorvastatin Calcium

Propolis

IIndonesia University

Cortrosyn

Acetylsalicyclic Acid (ASA)

Decadron

AAspen Global Incorporated

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

Cholesterol

NCT07428473

Clinical

Trials by Indication[1]

Cholesterol1 trial

A Phase 1 Open-Label Single Ascending Dose (Part 1) and Single or Multi-Dose Expansion (Part 2) Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of STX-1150 in Participants With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)

Recruiting·MMonash University·Phase 1·NCT07428473·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for STX-1150. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — STX-1150 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for STX-1150. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Monash University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: MMonash University

Related News